3 results
* To decrease mortality in MS-LCH by an early switch of patients with risk organ involvement, who do not respond to front-line therapy, to a more intensive treatment (Stratum III or Stratum IV).* To reduce reactivation rates and permanent…
Primary objective: To assess efficacy and safety (treatment of signs and symptoms) of Nanocort in subjects with active rheumatoid arthritis who are experiencing a flare/exacerbation in comparison to a standard of care medication (Depo-Medrol).…
Our primary objective is to assess the absence of binary restenosis rate, the reocclusion rate and target-lesion revascularization rate of endovascular treatment of advanced atherosclerotic lesions of the common iliac artery with a balloon…